Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.63 |
| ▸ | KDR | P35968 | 6/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.55 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.55 |
| ▸ | AXL | P30530 | 8/20 | 0.55 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259845 | 0.81 | MET (0.89) | METKDRRIPK2RIPK1RIPK3 | |
| Hydrochloric Acid SCHEMBL1259897 | 0.81 | MET (0.89) | METKDRRIPK2RIPK1RIPK3 | |
| SCHEMBL1260615 | 0.80 | MET (0.69) | METKDRRIPK2RIPK1RIPK3 | |
| SCHEMBL1260009 | 0.80 | MET (0.69) | METKDRRIPK2RIPK1RIPK3 | |
| Acetic Acid SCHEMBL1259623 | 0.80 | MET (0.88) | METKDRRIPK2RIPK1RIPK3 | |
| SCHEMBL1259967 | 0.77 | MET (1.00) | METKDRRIPK2RIPK1RIPK3 | |
| SCHEMBL30084609 | 0.77 | MET (0.59) | METKDRRIPK2RIPK1RIPK3 | |
| SCHEMBL27159253 | 0.77 | MET (0.59) | METKDRRIPK2RIPK1RIPK3 | |
| SCHEMBL1259902 | 0.77 | MET (0.62) | METKDRRIPK2RIPK1RIPK3 | |
| Hydrochloric Acid SCHEMBL1259611 | 0.77 | MET (1.00) | METKDRRIPK2RIPK1RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | MET 560/4885KDR 966/4885RIPK2 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.